公司資料
ImmuCell 股價、新聞與催化劑
- 股票代碼:
- ICCC
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
10.06 USD (-0.30%)
收盤價
最後更新: 2026年8月21日
88.6M USD
市值
股價為何變動
As of Aug 21, 2026, ICCC closed down 0.30% at $10.06. No new same-company headline was identified in the current news window.
公司概覽
Animal Health Biologics Company
ImmuCell develops biologic products intended to improve calf health and productivity. The company primarily serves dairy and livestock markets, with an emphasis on preventing early-life diseases such as neonatal calf diarrhea.
First Defense Franchise
The First Defense product line orally delivers antibodies derived from colostrum to provide immediate immune protection against major viral and bacterial causes of calf scours. Dual-Force and Tri-Shield are the franchise’s key growth products.
Commercial Execution
Growth depends on product availability, U.S. market demand, expansion of the commercial team, and distributor inventory cycles. The release did not identify a specific future clinical or regulatory milestone.
未來催化劑
- ImmuCell’s catalysts are animal-health product demand, manufacturing execution, and steady recurring revenue in veterinary biologics. The company moves on operating consistency rather than binary headlines.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。